APA (7th ed.) Citation

R, M. (2019). EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk? Pathology oncology research : POR, 25(4), 1665. https://doi.org/10.1007/s12253-019-00599-z

Chicago Style (17th ed.) Citation

R, Mormile. "EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is It Worth The Risk?" Pathology Oncology Research : POR 25, no. 4 (2019): 1665. https://doi.org/10.1007/s12253-019-00599-z.

MLA (9th ed.) Citation

R, Mormile. "EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is It Worth The Risk?" Pathology Oncology Research : POR, vol. 25, no. 4, 2019, p. 1665, https://doi.org/10.1007/s12253-019-00599-z.